Clinical Trials

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy


Study ID
SRA-MMB-301

NCT Number
NCT04173494 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0778

Principle Investigator
Dr. McCloskey II, James K.

Phase
III

Sponsor
Sierra Oncology


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now